Sign in

BRGX on OTC

BIOREGENX, INC.

BIOREGENX, INC. is an American computer programming, data processing services company.1 It is headquartered in Chattanooga, Tennessee.1 Its shares trade on OTC under the symbol BRGX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with J & Friends Holdings Ltd, TaoWeave, Inc. or GigaMedia Limited, or pick any stock.

  • TickerBRGX on OTC1
  • IndustryServices-Computer Programming, Data Processing, Etc.1
  • HeadquartersChattanooga, Tennessee1
  • Incorporated inNV2
  • Business address7407 Ziegler Road, Chattanooga, Tn 374212
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

This combination is meticulously designed to harness the power of artificial intelligence for vital sign estimation.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

81.1%Gross margin4
-67.1%Operating margin4
-83.2%Net margin4
-20.8%Revenue growth, 20254
$29.9KFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Nutritional brought in 87% of the revenue BIOREGENX, INC. broke down this way in fiscal 2025.

  1. Nutritional$1.6M487%down 11% from 2024
  2. Medical Testing$207.9K411%down 65% from 2024
  3. Wellness Devices$25.4K41%down 86% from 2024
  4. Other Sales$88440%down 72% from 2024
Products and services by year
Products and services20242025
Nutritional$1.8M$1.6M
Medical Testing$587.6K$207.9K
Wellness Devices$186.3K$25.4K
Other Sales$3.2K$884

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue13¢$350.9K
  • Research and development1¢$31.8K
  • Selling, general and admin75¢$2.0M
  • Interest11¢$299.6K

Out of $1.9M in revenue.4 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending23¢$9.1K
  • Kept or used elsewhere77¢$29.9K

Out of $39.0K of cash from operations.4

Financial statements

Revenue5674$1.9M in 2025+834% since 2021
0$1.0M$2.0M$3.0M$4.0M2021: $198.6K$198.6K20212022: $42.2K$42.2K2022−79%2023: $3.4M$3.4M2023+7992%2024: $2.3M$2.3M2024−31%2025: $1.9M$1.9M2025−21%
Gross profit574$1.5M in 2025+659% since 2021
0$1.0M$2.0M$3.0M2021: $198.0K$198.0K20212022: $42.2K$42.2K2022−79%2023: $2.3M$2.3M2023+5383%2024: $1.7M$1.7M2024−28%2025: $1.5M$1.5M2025−9%
Operating income5674-$1.2M in 2025+653% since 2021
-$30.0M-$20.0M-$10.0M02021: -$165.1K-$165.1K20212022: -$78.3K-$78.3K2022−53%2023: -$3.4M-$3.4M2023+4253%2024: -$22.8M-$22.8M2024+568%2025: -$1.2M-$1.2M2025−95%
Net income5674-$1.5M in 2025+1493% since 2021
-$30.0M-$20.0M-$10.0M02021: -$96.9K-$96.9K20212022: -$78.3K-$78.3K2022−19%2023: -$3.6M-$3.6M2023+4497%2024: -$23.1M-$23.1M2024+540%2025: -$1.5M-$1.5M2025−93%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Gross sales$1.9M$2.6M
Returns (Including common stock and warrants issued for refunds of $53,626 in 2024)-$8.0K-$261.7K
Net Sales$1.9M$2.3M
Cost of sales$350.9K$681.7K
Gross profit$1.5M$1.7M
Distributors incentives$15.9K$173.9K
Selling, general and administrative$2.0M$5.9M
Amortization expense$0$2.2M
Impairment expense$725.0K$16.2M
Total operating expenses$2.7M$24.4M
Loss from operations-$1.2M-$22.8M
Interest expense and financing costs-$299.6K-$290.7K
Weighted average common shares outstanding - basic959.7M shares912.4M shares
Weighted average common shares outstanding - diluted959.7M shares912.4M shares
Loss per share - basic$0.00-$0.03
Loss per share - diluted$0.00-$0.03
Net Loss-$1.5M-$23.1M
Foreign currency translation adjustment-$2.0K$3.0K
Other comprehensive loss-$1.5M-$23.1M
Common stock and warrants issued for refunds, value$53.6K

Compare BIOREGENX, INC. with another company

Corporate structure

BIOREGENX, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIOREGENX, INC.

  • Libertas Trust Filed SC 13D/A on BIOREGENX, INC., latest Jul 22, 2024 (3 filings since Apr 29, 2024)
  • JARA Trust Filed SC 13D/A on BIOREGENX, INC., latest Jul 19, 2024 (2 filings since Apr 29, 2024)
  • Wilshire Holdings Trust Filed SC 13D/A on BIOREGENX, INC., latest Jul 19, 2024 (2 filings since Apr 29, 2024)
  • BIOREGENX, INC. Chattanooga, Tennessee

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIOREGENX, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$159.7K4 Dec 31, 2025$200.7K4 Dec 31, 2024−20.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$58.4K7 Dec 31, 2024$125.4K7 Dec 31, 2023−53.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, net$07 Dec 31, 2024$49.4K7 Dec 31, 2023−100.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$106.9K4 Dec 31, 2025$111.1K4 Dec 31, 2024−3.7%
Finished goods$106.9K4 Dec 31, 2025$111.1K4 Dec 31, 2024−3.7%

Properties, in its own words

The Company is a global company that takes advantage of the ability to work remotely from many locations utilizing the latest video technology that has proven to be effective for businesses during the Covid-19 pandemic. We have been effectively working remotely for several years.

The Company is currently located at 7407 Ziegler Rd., Chattanooga, Tennessee 37421. BioRegenx shares the Chattanooga offices with NuLife. The offices consist of 1,000 sq ft. leased on a month-to-month basis with a monthly lease rate of $1,725. The lease payment is paid by NuLife. Additional facilities will be leased as needed.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led BIOREGENX, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William Resides2024

Chief financial officer

  1. William Resides2024

Chief operating officer

  1. Sherri Adams2024
2025
Board members and other officers (8)

Former names

  • FINDIT, INC.Mar 11, 2021 to Jan 18, 20242
  • ARTEMIS ENERGY HOLDINGS, INC.Dec 11, 2013 to Dec 11, 20132

Timeline

  1. Apr 14, 20258-K Executive or director change18
  2. Jan 22, 20258-K Executive or director change19
  3. Oct 11, 20248-K Executive or director change20
  4. Oct 9, 20248-K Completed an acquisition or sale; Unregistered sale of shares; Change in control21
  5. Jul 23, 20248-K Executive or director change22
  6. Jul 15, 20248-K Executive or director change23
  7. Jun 11, 20248-K Change of auditor; Earlier financial statements no longer reliable24
  8. May 22, 2024New chief executive William Resides becomes CEO11
  9. May 16, 20248-K Change of auditor25
  10. Apr 1, 20248-K Completed an acquisition or sale; Unregistered sale of shares; Change in control26
  11. Jan 6, 20238-K Entered a material agreement27

Filings

85 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 10 major events, 14 insider forms, 7 large holders, 32 other. The latest 20:

  1. May 20, 202610-Q FORM 10-Q FOR MAR 2026 EDGAR
  2. May 15, 2026NT 10-Q EXTENSION EDGAR
  3. Apr 15, 202610-K FORM 10-K FOR DEC 2025 EDGAR
  4. Apr 1, 2026NT 10-K EXTENSION EDGAR
  5. Nov 14, 202510-Q FORM 10-Q FOR SEP 2025 EDGAR
  6. Aug 14, 202510-Q FORM 10-Q FOR JUNE 2025 EDGAR
  7. May 15, 202510-Q FORM 10-Q FOR MAR 2025 EDGAR
  8. Apr 16, 202510-K/A FORM 10-K FOR DEC 2024 EDGAR
  9. Apr 15, 202510-K FORM 10-K FOR DEC 2024 EDGAR
  10. Apr 14, 20258-K EDGAR
  11. Apr 1, 2025NT 10-K EDGAR
  12. Jan 22, 20258-K EDGAR
  13. Jan 2, 20253 EDGAR
  14. Nov 14, 202410-Q FROM 10-Q FOR SEPT 2024 EDGAR
  15. Oct 11, 20248-K EDGAR
  16. Oct 9, 202410-Q FORM 10-Q FOR JUNE 2024 EDGAR
  17. Oct 9, 202410-Q/A FORM 10-Q AMENDMENT 2 EDGAR
  18. Oct 9, 20248-K/A EDGAR
  19. Aug 12, 2024NT 10-Q EXTENSION EDGAR
  20. Jul 23, 20248-K CURRENT REPORT EDGAR

The 85 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How BIOREGENX, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIOREGENX, INC.1
  • CIK0001593184
  • Employer ID (EIN)30-19124533
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)7370 Services-Computer Programming, Data Processing, Etc.1
  • SEC reviewing officeOffice of Technology, Division of Corporation Finance1
  • Business address7407 Ziegler Road, Chattanooga, TN 374211
  • Phone(866) 770-40671
  • Shares outstanding971,575,183 as of May 20, 202610
  • Public float$3.7M as of Jun 30, 20253
  • AuditorWeinberg & Company, P.A., Los Angeles, California PCAOB ID 572; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceDec 11, 20131
  • Filings107 in all: 10-Q (14), 3 (12), CORRESP (12), UPLOAD (11), 8-K (9), NT 10-Q (9), S-1/A (6), 10-K (5)1
    All 24 form types

    NT 10-K (5), SC 13D/A (4), PRER14C (3), SC 13D (3), 10-Q/A (2), 3/A (2), 10-K/A (1), 424B3 (1), 8-A12G (1), 8-K/A (1), D (1), DEF 14C (1), EFFECT (1), PRE 14C (1), PREM14C (1), S-1 (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) May 20, 2026
    Latest 8-K (8-K) Apr 14, 2025

Risk factors and legal proceedings

Legal proceedings

The Company is involved in disputes with certain parties, including parties that are former officers and board members and vendors associated with their activities and contractual issues. Such disputes arise from time to time in the ordinary course of conducting business. The disputes including matters involving amounts due to the Company, contract performance standards, options and warrants granted and liabilities under contracts or arrangements entered by the prior officers including with parties related to them. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While assurance cannot be given as to the outcome of these disputes, management does not currently believe that any of these matters, individually or in the aggregate are estimable or probable and is therefore unable to represent whether they would have a material adverse effect on the Company’s financial condition, liquidity or results of operations. It is reasonably possible that a change in the contingencies could result in a change in the amount recorded by the Company in the future.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30